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Introduction: Cotton rats are a suitable model for the study of influenza
disease symptoms and responses to influenza vaccination. We have previously
shown that two immunizations with 15 µg whole inactivated virus (WIV)
influenza vaccine could completely protect animals from infection with the
H1N1pdm09 virus.
Methods: To further explore the cotton rat model, we here investigated the
protective potential of a single intramuscular immunization and of prime/
boost intramuscular immunizations with a low amount of antigen.
Results: A single intramuscular immunization with doses more than or equal
to 0.5 µg WIV reliably evoked antibody responses and doses more than or
equal to 1 µg protected the animals from virus replication in the lungs and
from severe weight loss. However, clinical symptoms like an increased re-
spiration rate were still apparent. Administration of a booster dose significantly
increased the humoral immune responses but did not or only moderately
improved protection from clinical symptoms.
Conclusion: Our data suggest that complete and partial protection by influ-
enza vaccines can be mimicked in cotton rats by using specific vaccination
regimens.
KEYWORD S
cotton rats, humoral immune response, lung viral load, respiration rate, virus challenge,
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Abbreviation: WIV, whole inactivated virus influenza vaccine.
1 | INTRODUCTION
Cotton rats (Sigmodon hispidus) have been used as a
small animal model for respiratory virus infections
such as human parainfluenza virus, respiratory syncytial
virus, measles virus, human metapneumovirus, as
well as for the study of influenza virus infection and
pathogenesis.1–7 All these respiratory viruses can easily
replicate in cotton rats and induce pathogenesis similar
to that in humans. Unlike mice, cotton rats are suscep-
tible to clinical isolates of influenza virus without prior
adaptation of the virus.4,8,9 Indeed, cotton rats have been
infected successfully with a broad range of clinical in-
fluenza virus strains.4,6,10 Upon infection, cotton rats
show easily quantifiable disease symptoms like increased
respiration rate, weight loss, and hypothermia.11,12
Despite the positive results with cotton rats as a
model for influenza infection, there is so far limited
information on the performance of influenza vaccines
in cotton rats. Early studies evaluated the effect of
infection‐induced immunity on subsequent challenge
with homologous or heterologous virus strains.13,14 Later,
the studies were extended to ultraviolet‐inactivated
virus, seasonal trivalent split vaccine, and more recently
recombinant adenovirus vaccines and AS03‐adjuvanted
A(H1N1)pdm09 pandemic influenza vaccine.11,12,15–17
Some of these studies report on a reduced increase in
the respiration rate in immunized vs naïve cotton rats
upon challenge.13,15 Some studies investigated additional
parameters like lung virus titers and lung pathology
and/or determined induction of antibodies. However,
none of the studies gives a complete description of clin-
ical symptoms like changes in weight and temperature.
Moreover, none of the studies describes the evaluation
of vaccines against H1N1pdm virus, a clinically highly
relevant virus that is still in circulation.
We have shown earlier that through intramuscular
or pulmonary immunization with a high vaccine dose,
15 µg whole inactivated virus (WIV) vaccine, cotton rats
can be protected completely against replication of
H1N1pdm virus in the lungs and against the develop-
ment of severe clinical symptoms.18 To get more insight
into the model, we here assessed the effect of vaccine
dose and vaccination regimen on humoral immune
responses and the protective potential in detail.
To this end, we immunized cotton rats once or twice
with low doses of a WIV influenza vaccine derived from
an H1N1pdm09 vaccine strain and challenged the ani-
mals with a clinical isolate of H1N1pdm09 virus. Anti-
body titers in immunized animals correlated with vaccine
dose and were boosted by a second immunization.
Upon challenge, the lung virus titers on days 1 and 3
post‐challenge were strongly reduced as compared with
titers in control animals. Yet, immunization had limited
effects on clinical symptoms like tachypnea and disease
parameters or on induction of cytokines and Mx1 in
the lungs. We conclude that low or moderate vaccine
doses of WIV could protect outbred cotton rats partly
from the lethal virus infection. As such, the tested
vaccination regimens allow studying different scenarios
as encountered in humans.
2 | MATERIALS AND METHODS
2.1 | Vaccine and virus
NIBRG‐121, a vaccine strain produced from the A/
California/7/2009 virus, was obtained from NIBSC (Potters
Bay, UK) and grown in embryonated chicken eggs fol-
lowed by purification using sucrose gradient centrifuga-
tion. The virus was inactivated by overnight treatment
with 0.1% β‐propiolactone (Acros Organics, Geel, Belgium)
in citrate buffer (125mM sodium citrate, 150mM sodium
chloride, pH 8.2) at 4°C to produce WIV vaccine. In-
activation was followed by dialysis against HNE buffer
(145mM NaCl, 5mM HEPES, 1mM EDTA, pH 7.4, ster-
ilized by autoclaving). Inactivation of the virus was ver-
ified by inoculation of MDCK cells and the amount
of protein was determined by micro‐Lowry assay.
A clinical isolate of H1N1pdm (isolate E9‐6714) was
provided by the Department of Clinical Virology, UMCG.
The virus, to be called A/Cal/Gro in the following,
was diagnosed by quantitative polymerase chain reaction
(PCR) as being similar to A/California/7/2009 virus.
The virus was further amplified on MDCK cells, titrated
in cotton rats and was used as challenge virus. Virus
titer was determined by TCID50 titration.19 Whole
inactivated A/PR/8/34 (H1N1) and the X‐31 (H3N2,
reassortant strain of A/Aichi/68 and A/PR/8/34 viruses)
used for determination of cross‐reactive immunoglobulin
(IgG) enzyme‐linked immunosorbent assay (ELISA) were
kindly provided by NIBSC.
2.2 | Cotton rats and immunization
All animal experiments were approved by the Institutional
Animal Care and Use Committee of the University of
Groningen (IACUC‐RuG), The Netherlands. Outbred
female cotton rats at an age of 10 to 12 weeks were
purchased from Harlan Laboratories. The animals were
housed in individually ventilated cages with two cotton
rats per cage. All the cotton rats were injected with
implantable electronic ID transponders (Bio Medic Data
Systems Inc [BMDS], Seaford, DE) subcutaneously (s.c.)
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for individual identification and temperature measure-
ment. The weight of the cotton rats ranged between 120
and 150 g during the challenge phase. A sample size of
four animals per group was used based on literature.13,20,21
The study comprised two independent experiments,
the details of which are described in Table 1.
Cotton rats were vaccinated via the intramuscular
route with 100 µL vaccine distributed over the hind
limbs. Four weeks after the single immunization in
experiment 1 or the second immunization in experiment
2, cotton rats were challenged with A/Cal/Gro, 5 × 107
TCID50 in experiment 1 (on day 30) and 1 × 107 TCID50
in experiment 2 (on day 51). The virus in a volume
of 100 µL was distributed over both the nostrils using a
pipette. Both vaccination and challenge were carried
out under 5% isoflurane/O2 anesthesia. The two non-
treated control animals in experiment 2 received neither
vaccination nor challenge.
2.3 | Assessment of clinical symptoms
and sample collection
After challenge, cotton rats were followed daily for
determination of changes in weight, temperature and
respiration rate for 3 days in the first experiment and
10 days in the second experiment. Animals were weighed
by catching them into a preweighed cardboard roll.
Weight loss of 10% in 1 day or 15% from the day of
challenge were considered as criteria for the humane
endpoint. Ten days post‐challenge, the remaining cotton
rats were killed.
The respiration rate was measured by plethysmo-
graphy, as described previously.22 Briefly, the animal
was placed in a 1500mL air‐tight but transparent tube
of a whole‐body plethysmograph, which was connected
to a pressure transducer. The frequency of pressure
changes inside the tube was recorded and displayed as
breaths per minute (bpm). The mean respiration rate
of an animal was then calculated from a minimum of
four steady regions lasting for at least 15 seconds.
For many of the animals, if they breathed at a constant
rate, we even recorded the respiration for a minute
or more consecutively. The maximal variation between
the readings was ±5 to 10 bpm, thus about 1% to 3%.
Temperature was measured while the animal was re-
strained in the cardboard container using a DAS‐7008/9
detector for s.c. injected electronic ID transponders
(BMDS, Seaford, USA).
Blood was drawn on the day(s) of immunization, the
day of challenge and the days of sacrifice. Serum was
separated and stored at −20°C until assessment of IgG,
microneutralization (MN) and hemagglutination inhibi-
tion (HI) antibodies. A small part of the same lung was
stored in RNAlater (Qiagen, the Netherlands) for cyto-
kine profiling by quantitative real‐time PCR (qRT‐PCR).
2.4 | Lung virus titration
Equally sized parts of the lungs were collected in
1ml complete EPISERF medium (100 U/mL penicillin,
100mg/mL streptomycin, 1 M HEPES, 7.5% sodium
bicarbonate, all Life Technologies BV, Bleiswijk, The
Netherlands) and were homogenized, centrifuged, and
the supernatants were used for determination of viral
load in the lungs, as described previously.19 Virus
amounts are represented as log10 titer per mL of medium.
The limit of detection (LoD) was calculated using the
first dilution made; negative samples were assigned
a value corresponding to half of the LoD value for
calculation purposes.
2.5 | IgG and IgA enzyme‐linked
immunosorbent assay
IgG ELISA was performed by coating ELISA plates
(Greiner Bio‐One, Alphen a/d Rijn, The Netherlands)
with 0.3 µg/well of A/PR/8, H1N1pdm or X‐31 WIV in
coating buffer (17.8 mM Na2CO3, 22.5 mM NaHCO3,
pH9.6) overnight at 37°C. ELISA was done as described
TABLE 1 Experimental details of the
two animal experiments
Experiment 1 2
Groups and vaccine PBS control (n= 4) PBS control (n= 8)
0.5 µg WIV (n= 4) 1 µg WIV (n= 8)
1 µg WIV (n= 4) Nontreated control (n= 2)
5 µg WIV (n= 4)
Vaccination 1 dose, day 1 2 doses, day 1 and day 21
Virus challenge 5 × 107 TCID50 1 × 107 TCID50
(day 30) (day 51)
Abbreviations: PBS, phosphate‐buffered saline; WIV, whole inactivated virus.
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previously.23 IgG titers were calculated as log10 of the
reciprocal of the sample dilution corresponding to an
absorbance of 0.2 at the wavelength of 492 nm. LoD was
calculated using the first dilution made and the negative
samples were given half the value of the LoD value.
2.6 | MN assay and hemagglutination
inhibition
Serum samples taken on the day of the second im-
munization, the day of challenge and 10 days post‐
challenge were assessed for MN and HI antibodies
against A/California/2009 virus using a previously de-
scribed protocol,23,24 respectively. Titers are presented
as log2 HI titers for individual cotton rats. LoD was cal-
culated using the first dilution made and the negative
samples were given half the value of the LoD value.
2.7 | Cytokine measurement by
quantitative real‐time polymerase chain
reaction
For determination of cytokine expression in the lungs, the
lungs stored in RNAlater were homogenized using a pestle
and RNA was extracted with the help of the QIAGEN
RNeasy extraction mini kit (Qiagen, Hilden, Germany).
Complementary DNA was synthesized with a PrimeScript
RT‐PCR Kit (Takara, Westburg, Leusden, the Netherlands)
using 500 ng RNA. qPCR was run with specific anti‐cotton
rat primers for Mx1, Mx2, IFNγ, IFNα, IL1β, IL4, IL6, and
IL12 (primer sequences, see Table S1). Primers were de-
signed with help of the program Primer Blast, using cotton
rat sequences from NCBI BLAST. The specificity of the
primers was validated by checking if there was a single melt
curve for all samples tested. Glyceraldehyde 3‐phosphate
dehydrogenase (GAPDH) was used as a housekeeping gene.
PCR cycling conditions were set as 10minutes 95°C
followed by 40 cycles of 15 seconds 95°C and 1minute 60°C
on an Applied Biosystems’ StepOnePlus real‐time PCR
system. SYBR green ROX‐mix used was from Westburg
(Leusden, the Netherlands).
For analysis, mean CT values of GAPDH per sample
were subtracted from the mean CT values of the cytokine
for the same animal to calculate ΔCT values. ΔΔCT values
were then calculated by subtracting ΔCT of the non-
treated cotton rats from ΔCT of the vaccinated and non-
vaccinated cotton rats that were challenged and killed
on day 1 and day 10 post‐challenge. The fold change
was then calculated. Cytokines are represented as log2
fold changes in vaccinated and nonvaccinated cotton rats
with respect to nontreated cotton rats.
2.8 | Statistical analysis
The statistical analysis was performed using GraphPad
Prism 5 software (GraphPad Software, La Jolla, CA)
with which the graphs were plotted as well. The
nonparametric Mann‐Whitney U test was used to test
if the differences between two groups, that is, vacci-
nated and nonvaccinated cotton rats, with respect to
different parameters were significant. A P value of less
than 0.05 was considered significant.
3 | RESULTS
3.1 | Systemic immune response after
a single vaccination
To assess the immune response induced by a single
IM immunization with WIV, sera were collected on
the day of immunization and the day of challenge
and serum IgG titers were evaluated by ELISA. On
the day of immunization, all cotton rats were sero‐
negative for influenza (data not shown). On the day
of challenge, all vaccinated cotton rats had developed
antibodies with a titer of 103 or higher. Compared with
IgG titers induced by 0.5 µg WIV, significantly higher
IgG titers were induced by 1 and 5 µg WIV (Figure 1),
yet, the differences were rather small (about 2.5‐fold).
No difference was found between the IgG titers
induced by 1 and 5 µg WIV. Thus, all vaccine doses
induced robust serum IgG responses upon a single
vaccination.
FIGURE 1 Systemic immune response after a single
vaccination. Serum IgG responses were evaluated 30 days after a
single immunization with the indicated amounts of WIV. IgG titers
are presented as log10 titers for individual cotton rats with means
per group (n= 4). LoD is indicated at 2 with a dashed line and
significance is represented as *P< .05. IgG, immunoglobulin;
LOD, limit of detection; PBS, phosphate‐buffered saline;
WIV, whole inactivated virus
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3.2 | Effect of a single immunization on
clinical symptoms after virus challenge
We next assessed the effect of a single vaccination with
low and moderate vaccine doses on disease symptoms
and lung virus replication upon infection. To this end,
cotton rats were i.m. injected with a single dose of either
PBS, 0.5, 1, or 5 µg WIV followed by homologous chal-
lenge with a dose of 5 × 107 TCID50 H1N1pdm 30 days
later. Upon challenge, clinical symptoms like weight
loss, respiration rate, and temperature were assessed for
3 days in vaccinated and nonvaccinated cotton rats.
Two animals from the PBS control group were found
dead on day three post‐challenge. The two remaining cotton
rats from the PBS group did not show considerable weight
loss on day 1 post‐challenge, however, their weight reduced
over the next 2 days (Figure 2A). Two cotton rats from the
0.5 µg WIV group were found dead on day 2 post‐challenge,
the other animals from this group did not show much
weight loss (Figure 2B). Animals from the 1 and 5 µg WIV
groups lost no or little weight (Figure 2C,D). The animals
from the PBS control group and the 0.5 µg WIV group which
deceased shortly upon infection showed a slight drop in
temperature before death and an additional animal from the
PBS group showed a substantial decrease in body tempera-
ture on day 3 (Figure 2E). The temperature was not affected
by the virus infection in other animals (Figure 2E‐H).
All four cotton rats from the PBS control group pre-
sented with a significant increase in respiration rate on day
two post‐challenge and then the respiration started to
normalize (Figure 2I). Also, all the animals in the 0.5 µg
WIV group showed increase in respiration rate on day 2
(Figure 2J). In the 1 µg WIV group, two of the animals
demonstrated a marked and sustained increase in respira-
tion rate post‐challenge, the remaining two animals pre-
sented with only a moderately increased respiration rate,
which returned to normal values by day three (Figure 2K).
Cotton rats in the 5 µg WIV group also showed increased
respiration on day 1 post‐challenge. However, on day 2, the
respiration rate in these animals started to decrease and
was significantly lower than the respiration rate in the
mock‐immunized control animals on day 2 (*P= .0286).
For three of the four animals the respiration rate came back
to the baseline on day three (Figure 2L). Hence, the re-
spiration rate was the most sensitive parameter of infection
in the used cotton rat model.
FIGURE 2 Effect of a single immunization on clinical symptoms after virus challenge. Cotton rats mock‐immunized with PBS or
immunized once with 0.5, 1, or 5 µg WIV and challenged on day 30 with 5 × 107 TCID50 of homologous A/Cal/Gro were followed for 3 days
and weight (A‐D), temperature (E‐H), and respiration rate (I‐L) were recorded. Discontinued line with X symbol indicates dead animal.
PBS, phosphate‐buffered saline; WIV, whole inactivated virus
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In conclusion, immunization with a sufficiently high
dose of WIV prevented infection‐induced death of the
cotton rats but provided limited protection against
clinical symptoms. Some of the control animals and of
the 0.5 µg WIV group died rapidly without prior overt
signs of distress.
3.3 | Effect of a single immunization on
lung virus titers
To assess the effect of the immunization on virus re-
plication, immunized and PBS‐treated animals were kil-
led 3 days post‐challenge to evaluate lung virus titers. As
two animals from each of the PBS treated and the 0.5 µg
WIV groups were found dead before day 3, virus titers
could not be retrieved from them. The two surviving
cotton rats from the PBS group showed titers of 103.2/mL
and 103.5/mL, respectively. Of the surviving animals from
the 0.5 µg WIV group, one had a virus titer of 102.8/mL
while the other had no detectable virus in the lung.
Animals vaccinated with 1 or 5 µg WIV were all free of
virus in the lungs 3 days post‐infection (Figure 3). No
virus was found in the nose of any of the animals. Thus,
even a single vaccination with a moderate vaccine dose
of 1 µg reliably protected against replicating virus in the
lungs upon challenge.
3.4 | IgG responses after prime/boost
vaccination and challenge
In the case of a newly emerging virus, naïve individuals
are expected to benefit from a booster immunization to
achieve protective levels of immunity. To mimic this si-
tuation, we immunized cotton rats twice with a moderate
dose of 1 µg WIV and challenged them 1 month after the
second immunization. To measure the immune response
induced by immunization and/or infection, IgG ELISA
was performed on serum samples taken from vaccinated
as well as mock‐vaccinated cotton rats on the days of
immunization (d0, d21), the day of challenge (d50), and
10 days post‐challenge (d60). IgG titers were determined
against homologous NIBRG‐121 (Figure 4A). None of the
animals showed any influenza‐specific IgG on the day of
the first immunization. In line with the first experiment,
cotton rats from the WIV‐immunized group developed
IgG titers of around 103.8 after the first immunization;
these titers increased slightly but significantly after the
second vaccination. Interestingly, upon challenge, IgG
titers increased further indicating a booster by the in-
fection itself. For nonvaccinated cotton rats, there was no
serum IgG on the day of challenge (Figure 4B), but
10 days post‐challenge, virus‐specific IgG was readily
detectable in the two surviving animals confirming
successful infection.
To assess the cross‐reactive potential of these IgG
antibodies, ELISA was performed to measure antibodies
against heterologous A/PR/8 H1N1 and heterosubtypic
X‐31 H3N2. All cotton rats vaccinated twice with 1 µg
WIV showed IgG responses to A/PR/8 but titers were
about 1 log lower than those against the homologous
virus (Figure 4C). Yet, only two of the four vaccinated
cotton rats had IgG cross‐reactive with X‐31 and the titers
were much lower than those to the homologous virus
(Figure 4D).
3.5 | Assessment of the functional
potential of systemic antibodies by HI
and MN upon prime/boost vaccination
To assess the functional potential of the serum IgG, HI
and MN assays were performed using homologous
NIBRG‐121. In line with the IgG antibody responses, HI
(Figure 5A) and MN (Figure 5B) antibodies were readily
detected after two vaccinations with 1 µg WIV and in-
creased further after challenge. For nonvaccinated cotton
rats, HI (Figure 5C) and MN (Figure 5D) antibodies were
undetectable before challenge but were present 10 days
post‐challenge although at lower levels than in vacci-
nated animals. We also checked for the cross‐neutralizing
potential of serum antibodies against A/PR/8 H1N1 and
X‐31 H3N2 virus. However, despite the presence of cross‐
reacting antibodies detected by ELISA these antibodies
could not neutralize the heterologous and heterosubtypic
viruses (results not shown).
FIGURE 3 Effect of a single immunization on lung virus
titers. The surviving cotton rats from the experiment described in
the legend to Figure 2 were killed 3 days post‐challenge and lung
virus titers were determined. Virus titers for individual cotton rats
and the mean titers per experimental group are depicted. LoD for
the virus titers is indicated at 0.3 with a dashed line and negative
samples are assigned a value corresponding to half of the LoD.
LOD, limit of detection; PBS, phosphate‐buffered saline
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FIGURE 4 IgG responses after prime/boost vaccination and challenge. Serum samples collected on day 0, after the first vaccination
(d21), on the day of challenge (d50), and 10 days post‐challenge (d60) were used for the determination of IgG titers. IgG ELISA was
performed for sera of (A) vaccinated cotton rats and (B) nonvaccinated cotton rats. Cross‐reactive IgG against A/PR/8 H1N1 (C) and against
X‐31 H3N2 (D) was measured in d50 serum samples. Titers are represented as log10 titers with significance *P< .05 and **P< .01. LoD for
the IgG titers is indicated at 2 with a dashed line. ELISA, enzyme‐linked immunosorbent assay; IgG, immunoglobulin; LOD, limit of
detection; n.d, not determined; PBS, phosphate‐buffered saline; WIV, whole inactivated virus
FIGURE 5 Assessment of the functional potential of systemic antibodies by HI and MN assays. Serum samples were collected at the second
vaccination (d21), day of challenge (d50), and 10 days post‐homologous challenge (d60) and functionality of the IgG was measured by HI
(A,C) and MN (B,D) assays for vaccinated (A,B) and nonvaccinated cotton rats (C,D). HI and MN antibody titers against NIBRG‐121 virus are
represented as log2 titers. Significance as *P< .05, **P< .01. LoD for the MN titers is indicated at 4.32 and LoD for the HI titers is indicated at
2.58, both indicated with a dashed line. HI, hemagglutination inhibition; LOD, limit of detection; MN, microneutralization; n.d, not determined
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3.6 | Effects of prime/boost vaccination
on clinical symptoms post‐challenge
As a single immunization with 1 µg WIV completely pro-
tected from virus replication but not from clinical symp-
toms in the first experiment, we next assessed whether the
protection provided by WIV could be improved by giving
a booster vaccination. For this purpose, in the second
experiment, cotton rats were vaccinated twice with 1 µg
NIBRG‐121 WIV with a 21‐day interval and were chal-
lenged with 1 × 107 TCID50 of homologous A/Cal/Gro 30
days later. The lower challenge dose compared with the first
experiment was chosen to slow down the disease process.
Upon challenge, animals were followed daily for 10 days
for changes in weight, temperature and respiration rate.
Despite the fivefold lower virus challenge dose, two of
the four mock‐vaccinated cotton rats were found dead in
the cage on days 3 and 4 post‐challenge. The remaining
two cotton rats from the control group displayed minor
weight loss but survived until the end of the follow‐up
period (Figure 6A). Cotton rats vaccinated twice with
1 µg WIV lost some weight until day 2 post‐challenge
(Figure 6B), thereafter, the weights were stable till sa-
crifice. Interestingly, two control cotton rats that were
neither vaccinated nor challenged also lost also some
weight over time (Figure 6C) and did not regain it, which
might suggest that daily handling caused a stress re-
sponse affecting eating or drinking behavior. Tempera-
ture was not affected in the infected animals except for
one of the mock‐vaccinated cotton rats, which showed a
decline in temperature 1 day before death (Figure 6D‐F).
All of the mock‐vaccinated cotton rats showed a sig-
nificant increase in respiration rate between the day of
challenge and day 2 post‐challenge, indicating successful
infection (Figure 6G). One of the four cotton rats reached
a respiration rate of around 460 and was found dead
2 days later. Cotton rats vaccinated with 1 µg WIV also
presented with a significantly higher respiration rate on
FIGURE 6 Effects of prime/boost vaccination on clinical symptoms post‐challenge. Cotton rats were injected with PBS, immunized
twice with 1 µg WIV, or were left untreated. Thirty days after the second immunization, immunized and mock‐immunized animals were
challenged with 1 × 107 TCID50 of homologous virus, nontreated animals were again left untreated. After challenge, animals were followed
for weight loss (A‐C), change in temperature (D‐F), and respiration rate (G‐I). Discontinued line with X symbol indicates dead animals.
PBS, phosphate‐buffered saline; WIV, whole inactivated virus
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day 2 post‐challenge as compared with the day of chal-
lenge (Figure 6H). There was no statistically significant
difference in the day 2 respiration rate between mock‐
vaccinated and vaccinated animals in this experiment
(P= 1.0000). After day 2, the respiration rate started to
return to normal. Nontreated cotton rats did not show
much change in the respiration rate compared with their
baseline respiration rate (Figure 6I).
3.7 | Effect of prime/boost vaccination
on lung virus titers after challenge
One day post‐challenge, the peak day of virus in the lungs
according to the literature,20 half of the animals from the
vaccinated and the mock‐vaccinated group were killed
to evaluate the viral load in the lungs. All cotton rats
from the mock‐vaccinated group had virus in their lungs,
with a mean titer of 105.51/mL (Figure 7). In contrast, out
of four immunized cotton rats, two did not show
detectable virus and the remaining two showed reduced
titers (101 and 103.8) as compared with the virus titers
in nonvaccinated cotton rats (lowest titer: 104.4). Thus,
a booster vaccination with a moderate vaccine dose
provided significant protection (P= .0294) from early
virus replication in the lungs.
3.8 | Effect of prime/boost vaccination
on infection‐related expression of Mx and
cytokine genes in the lung
To evaluate the effects of vaccination on expression of
infection‐related genes in the lungs upon challenge,
qRT‐PCR was performed on messenger RNA (mRNA)
isolated from lung tissue; mRNA derived from lungs
of nontreated cotton rats was used to set the baseline
expression.
Mx proteins can inhibit virus replication and have
been described to be strongly induced in the lungs of
influenza‐infected cotton rats.25,26 Infection clearly led to
increased expression of Mx1 1 day post‐challenge in both
vaccinated and nonvaccinated cotton rats but levels had
returned to normal or even less than normal by day 10
(Figure 8A). In contrast, Mx2 was strongly down-
regulated (around fivefold) in cotton rats from both
groups on day 1 post‐challenge (Figure 8B), but reached
baseline levels again by day 10. There was no difference
in expression of Mx1 and Mx2 between nonvaccinated
and vaccinated animals.
Another response to influenza infection in cotton rats
is the upregulation of cytokine expression.20 We observed
that infection led to increased expression, particularly of
IFNα, IFNγ, IL1β, and IL6 on day 1 post‐challenge. By
day 10, expression of these cytokines had declined
again, though not in all cases, to baseline (Figure 8C‐F).
Although expression of the aforementioned cytokines
clearly peaked shortly after infection and then declined
again, expression of IL4 and IL12 did not show such a
trend (Figure 8G,H) but rather showed a moderate but
sustained increase. Vaccination did not have significant
effects on cytokine expression in the lungs upon infec-
tion. Only for IFNα, there was a trend to lower expression
in vaccinated animals and IL4 expression was higher in
three out of four vaccinated animals as compared with
nonvaccinated animals on day 1 post‐challenge.
4 | DISCUSSION
The aim of this study was to assess the humoral immune
responses and the degree of protection (clinical and vir-
ological) induced upon use of different influenza vacci-
nation regimens, single immunization with different
vaccine doses and prime/boost immunization with a
moderate vaccine dose. We demonstrate that all im-
munized animals developed a humoral immune response
against the vaccine strain. A single immunization with a
dose more than 0.5 μg antigen as well as prime/boost
immunization before virus challenge resulted in reduc-
tion of lung virus titer (on day 1 or day 3) and improved
survival but had rather moderate effects on clinical
symptoms. In particular, increased respiration rate, the
most sensitive parameter of infection, was only slightly
ameliorated in vaccinated animals. Furthermore, upon
prime/boost vaccination, gene expression in the lungs of
the vaccinated animals was found to be similar to the
FIGURE 7 Effect of prime/boost vaccination on lung virus
titers after challenge. Thirty days after the second vaccination,
cotton rats were challenged with 107 TCID50 homologous
A/Cal/Gro by i.n. administration. One day post‐challenge, lung
virus titers were determined by TCID50. Virus titers of individual
animals and the mean virus titer per experimental group are
depicted. Significance is represented as *P< .05. LoD for the virus
titers is indicated at 0.3 with a dashed line. LOD, limit of detection
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gene expression in the lungs of nonvaccinated animals.
Although we used outbred cotton rats, we found varia-
tion among the animals to be acceptable.
As a challenge virus, we used a clinical isolate of
H1N1pdm09 virus. Upon whole respiratory tract chal-
lenge, we could readily detect the virus in the lungs of
the cotton rats on days 1 and 3 post‐infection, indicating
successful infection. Yet, we observed no or very little
effect of the infection on weight loss and temperature.
This is in line with a study by Blanco et al and our own
study, which previously reported that infection with
H1N1pdm09 does not cause overt weight loss and/or
drop in temperature in cotton rats in contrast to infection
with other influenza virus strains.18,26 However,
H1N1pdm09 infection led to a marked increase in the
respiration rate of the animals, which was in line with
what we have reported earlier.18 In nonvaccinated ani-
mals, the peak of increased respiration rate was on day 2
post‐challenge, which correlates with the peak of lung
histopathology on day 2 as reported by Blanco et al. In
the second study, although we used five times less virus,
interestingly, an increased respiration rate was also
observed in vaccinated animals (upon prime‐boost vac-
cination). This indicates that vaccinated animals still
developed some disease symptoms despite the fact that
lung virus titers were strongly reduced or even below
detection limit. We attribute this to the moderate dose of
vaccine used in this study.
When investigating gene expression in the lungs of
infected cotton rats, we found upregulation of Mx1
mRNA as well as of mRNAs encoding IFNα, IFNγ, IL1β,
and IL6, indicating induction of an antiviral response.
This result corroborates the findings from earlier studies,
which report IFN expression in influenza‐infected cotton
rats to correlate with replicating virus in the lung and
to mediate antiviral responses by induction of Mx1 genes
FIGURE 8 Effect of prime/boost vaccination on gene expression in the lungs upon infection. Cotton rats were (mock‐)immunized,
boosted and challenged as previously described. On day 1 and day 10 after virus challenge, expression of cytokine mRNA in lungs of the
animals was assessed by qRT‐PCR with gene‐specific primers using the housekeeping gene GAPDH as a reference. GAPDH, glyceraldehyde
3‐phosphate dehydrogenase; mRNA, messenger RNA; qRT‐PCR, quantitative real‐time polymerase chain reaction
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and other response modifiers.21,26,2720,25,28 Many of these
cytokines are expressed early upon infection and at this
time point virus replication peaks as well in cotton
rats.20,28 And that is why day 1 post‐challenge was an
interesting time point to assess cytokine expression. In
contrast to earlier reported results, we observed a strong
downregulation of Mx2 mRNA on day 1 post‐challenge
in both vaccinated and nonvaccinated animals.25 The
reason for this discrepancy is unknown but could possi-
bly be related to the virus strain used (A/Wuhan.359/95
H3N2 in the previous study, H1N1pdm09 here). Mx2
is not involved in the response to influenza virus
infection27,29,30 and its downregulation might thus
simply be the result of a general shut down of host gene
expression as observed in influenza‐infected cells.31,32
Levels of expression of Mx1 and the mentioned cytokines
were similar for naïve and vaccinated animals. This
further corroborates that for the vaccination regimens
investigated in this current study, sterilizing immunity
could not be achieved, which is why we do not see a
difference in the expression pattern of these cytokines
between vaccinated and nonvaccinated animals. We
attribute this to the challenge virus.
When evaluating the effect of vaccination, we ob-
served that a single i.m. injection of WIV even with a low
dose of 0.5 µg was sufficient to induce humoral immune
response and to reduce (0.5 µg) or abolish (1 and 5 µg
WIV) virus replication in the lungs. A prime/boost
vaccination regimen with a moderate antigen amount of
1 µg increased the serum antibody titers significantly.
Interestingly, the HAI titers were even of the same
magnitude as the ones induced by two immunizations
with 15 µg WIV in our previous study.18 Although there
was a disconnect observed among the titers of IgG, HAI
and MN antibodies, the overall trend of responses was
similar. However, in contrast to the previously published
study, we did not observe complete protection against
clinical symptoms in this current study.
There are several studies evaluating the effect of
influenza vaccination in cotton rats; however, these
studies do usually not investigate clinical symptoms in
detail. A study by Yim et al12 showed that a single i.m.
vaccination with a low dose of trivalent inactivated
vaccine, FluLaval, was efficacious in inducing antibody
responses in cotton rats and preventing virus replication
in the lungs but a booster vaccination was needed
to protect also from virus replication in the nose. Un-
fortunately, no data on disease symptoms are provided.
In a study by Crosby et al, a single vaccination with a
low dose of an HA‐expressing AAV vaccine could only
partly protect the animals from lung virus replication
in spite of effectively inducing anti‐HA antibodies.16
These and our own observations suggest that complete
protection of cotton rats against influenza infection
might require more than HA‐specific antibodies alone.
For example, it has been reported that passively trans-
ferred antibodies against M2e can partly protect cotton
rats against influenza‐induced tachypnea indicating a
role for anti‐M2e in protection.11 It might be that the
low or moderate doses of vaccine as used in the current
study were insufficient in inducing anti‐M2e antibodies
and other so far unidentified immune mechanisms and
thus could not confer complete protection.
There are certain limitations of this study which can
be overcome in future studies. Our study focusses on
the effects of vaccination‐induced humoral immunity.
However, the effect of different vaccination regimens
on T cell immunity would also be interesting to explore.
Furthermore, for this proof‐of‐concept study, we used a
sample size of four animals per group like many other
cotton rat studies do. Yet, to accommodate for inter‐
animal variation and possible loss of animals, in future
studies with outbred cotton rats, larger group sizes
should be used. To improve the immune response and
in turn the protection, vaccine dose could be increased
or other routes of vaccination or inclusion of adjuvants
could be tested.
In conclusion, outbred cotton rats can be a good
model for influenza infection and vaccine evaluation
studies, as infection with clinical isolates is possible
without preadaptation and immune responses can be
easily induced by vaccination. Protective effects of vac-
cination should be investigated by assessing not only
virus titers but also by evaluating clinical symptoms,
especially tachypnea, as a particularly sensitive para-
meter. Doing so enables to mimic complete and partial
protection from influenza by using specific vaccination
regimens. Being small, affordable and susceptible to
clinical influenza virus isolates, cotton rats have their
place between the clinically less relevant inbred mouse
model and the expensive ferret model for the evaluation
of influenza vaccine candidates.
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